-transparent.png){kind=logo}
Tilorone hydrochloride, a drug able selectively to affect T-lymphocyte fuction, when incorporated (at three different concentrations 0.1, 0.04, 0.02 microgram/ml) in lymphocyte culture, stimulated by 50 microgram/ml of E. coli LPS (026:B6 W), is able to abolish LIF production, due to endotoxin stimulation. Such effect is, may be, due to an impairment of T-cell activity, since tilorone at the same concentration decreases the number of ARFC and TRFC, which are specific markers for T-cells.
Related Publications
E Jirillo, and
R Monno, and
I Munno, and
A De Santis, and
D Fumarola
January 1977,
Bollettino della Societa italiana di biologia sperimentale,
E Jirillo, and
R Monno, and
I Munno, and
A De Santis, and
D Fumarola
December 1972,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
E Jirillo, and
R Monno, and
I Munno, and
A De Santis, and
D Fumarola
April 1978,
Cellular immunology,
E Jirillo, and
R Monno, and
I Munno, and
A De Santis, and
D Fumarola
January 1984,
Polish journal of pharmacology and pharmacy,
E Jirillo, and
R Monno, and
I Munno, and
A De Santis, and
D Fumarola
April 1977,
Toxicology and applied pharmacology,
E Jirillo, and
R Monno, and
I Munno, and
A De Santis, and
D Fumarola
February 1988,
Immunology,
E Jirillo, and
R Monno, and
I Munno, and
A De Santis, and
D Fumarola
January 2003,
Cytokine,
E Jirillo, and
R Monno, and
I Munno, and
A De Santis, and
D Fumarola
January 2017,
International journal of molecular medicine,
E Jirillo, and
R Monno, and
I Munno, and
A De Santis, and
D Fumarola
May 2019,
Protein expression and purification,
E Jirillo, and
R Monno, and
I Munno, and
A De Santis, and
D Fumarola
February 1981,
Clinical immunology and immunopathology,
